Chinese Premier raises concerns over leukemia medicine shortage

22 November 2017

Chinese Premier Li Keqiang has stepped in to encourage more domestic production of leukemia medication mercaptopurine, after an acute shortage has left many in China scouring social media and traveling abroad in search of supplies.

Mercaptopurine tablets are a potent therapy used for certain types of acute leukemia in combination with other drugs.

On the State Council website, Premier Li stated: "It is another heavy blow to the families suffering from leukemia. Related departments should take measures to increase the drug supply.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical